Acorn Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Acorn Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-18	Closed	-$2K	–	554
2018 Q1	$2K	Hold	18	–	–	﹤0.01%	712
2017 Q4	$2K	Buy	+18	New	+$1.56K	﹤0.01%	686

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Acorn Wealth Advisors's BMRN Position: Q2 2018 in Review

Acorn Wealth Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 18 shares — an estimated $2K sold.

Acorn Wealth Advisors first reported a position in BMRN in Q4 2017 and held it in 2 quarters. The position peaked at $2K in Q1 2018. 448 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

Acorn Wealth Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Acorn Wealth Advisors sold 18 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $2K.
Acorn Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 2 quarters.
Acorn Wealth Advisors's BioMarin Pharmaceuticals position peaked at $2K in Q1 2018.
448 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on Acorn Wealth Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.